ReviewJournal of inflammation research2026
SIRT1 as a Key Regulator in Rheumatic Diseases: Integrating Molecular Insights with Traditional Chinese Medicine Approaches.
Review in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatic diseases are characterized by chronic inflammation and immune dysregulation that profoundly impair patients' quality of life, yet their underlying pathogenic mechanisms remain incompletely elucidated. Sirtuin 1 (SIRT1), an NAD⁺-dependent deacetylase, has emerged as a pivotal regulatory hub that integrates inflammatory signaling, cellular stress responses, metabolic reprogramming, and epigenetic control. Through key pathways (e.g. NF-κB and AMPK), SIRT1 modulates immune activation, synovial pathology, cartilage degeneration, and systemic inflammatory phenotypes across a spectrum of major rheumatic diseases, including rheumatoid arthritis (RA), osteoarthritis (OA), systemic lupus erythematosus (SLE), and gout. To summarize the current body of evidence, we conducted a targeted literature search across major databases (e.g. PubMed and Web of Science) for publications published up to 2025. We included peer-reviewed original studies and reviews that investigated (a) SIRT1 expression/activity and its downstream mechanisms in rheumatic diseases, or (b) traditional Chinese medicine (TCM) compounds or formulations with experimental or clinical evidence of SIRT1 modulation. We synthesized mechanistic insights spanning immunometabolism, inflammasome regulation, autophagy/ferroptosis, and non-coding (nc)RNA-mediated epigenetic networks. Additionally, we critically discussed context-dependent-and at times conflicting-observations across experimental models and human studies. Furthermore, we evaluated the current landscape of TCM-based SIRT1 modulation and found that most evidence remains preclinical; translational efforts are constrained by bioavailability, standardization, dosing, and reproducibility. Taken together, this integrative review highlights SIRT1 as a biologically important but context-dependent regulatory node in rheumatic diseases. It also emphasizes that SIRT1-targeted interventions (including TCM-derived modulators) require biomarker-guided stratification, pharmacological validation, and rigorously designed clinical studies before they can be translated into clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.